New obesity drug formulation put to the test
NCT ID NCT07407348
First seen Feb 16, 2026
Summary
This study is testing whether two different versions of the drug survodutide are equally effective in the body. It involves 80 healthy overweight or obese adults who will receive both formulations in a crossover design. The goal is to see if the new formulation matches the original in terms of drug levels in the blood.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Quotient Sciences
RECRUITINGNottingham, NG11 6JS, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
survodutide
What this could lead to
If successful, this could confirm that a new formulation of survodutide works as well as the original, potentially leading to a more convenient or cheaper treatment for obesity.
What could go wrong
This is an early phase 1 trial focused on drug levels in the body, not on weight loss or health outcomes. It may not lead to a better treatment, and side effects are still being studied.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.